Alkermes PLC (NAS:ALKS)
$ 29.65 0.15 (0.51%) Market Cap: 4.80 Bil Enterprise Value: 4.25 Bil PE Ratio: 15.21 PB Ratio: 3.71 GF Score: 69/100

Alkermes Plc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 07:15PM GMT
Release Date Price: $28.15 (-2.86%)
Jessica Fye JPMorgan Chase;Co.;Analyst

&-

Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42 Annual Healthcare Conference today with Alkermes. Richard Pops, the company CEO is going to give a presentation on the business and then we're going to go into Q&A after that.

If you have a question in the room, you can raise your hand, and we'll bring you a microphone or you can submit questions through the portal. But with that, let me that's over to Richard.

Richard Pops Alkermes plc;Chairman;CEO

&

Great, thank you, Jess. I'm joined here with via Blair Jackson and Iain Brown as well. So good morning, everybody. So I've been looking forward to giving this presentation for a couple of years. This is a new company. Alkermes in 2024 is a profitable pure play company in the aspect of the biopharmaceutical industry that is taking on, I think, a renewed level of strategic importance in this neuroscience.

So we'll talk about that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot